We are reducing the minimum investment in credit investment opportunities

Glycanostics - Giasay®

Highly accurate and unique blood-based early-stage cancer diagnosis

CompaniesEquityActive

Glycanostics - Giasay®

About the investment opportunity

Glycanostics’ patented technology enables the diagnosis of up to 11 types of cancer. In a new investment round on the Crowdberry platform, the company will use the targeted $10m in capital to develop an already existing, painless and reliable diagnostic method by transferring this tested prototype to new indications such as breast cancer, as well as to cover the associated costs or mass production of the diagnostic test.

Discussions are currently underway with several investment funds for a potential €5m co-investment to complement the €5m funding of this investment opportunity from Crowdberry investors. This creates unique conditions for private investors to participate in the financing of this Slovak Life Sciences company with global potential. This brings the total investment to €10m of growth capital.

Use of investment

  • Cost of transfer of the test to the manufacturing site and start-up of mass production
  • Coverage of operating costs
  • Costs associated with expansion into new markets

About Glycanostics

After a successful first investment round on the Crowdberry platform, which enabled the development of a unique prostate cancer diagnostic and its launch on the market, the Slovak biotech company Glycanostics is developing a diagnostic for other indications such as breast cancer.

The company was founded in 2017 by two renowned Slovak scientists – Ján Tkáč and Tomáš Bertók. With experience at prestigious foreign universities, more than 160 research papers and 3,900 citations, they are among the world's most respected scientists. They focus on the field of cancer diagnostics through specific biomarkers in the blood, which are also the subject of research by leading pharmaceutical companies. Joining the team as CEO is Eva Kováčová, who has over 28 years of global experience in the pharmaceutical industry.

The company's goal is to bring accurate, non-invasive and affordable blood-based cancer tests to the market, without unnecessary, painful and costly biopsies.

Proof of the company's success is the recent successful launch of the Giasay® PROSTATE product – a prostate cancer diagnostic that is already being actively used by Slovak urologists and patients. The principle on which this diagnostic method is based has the potential to detect other types of cancer, such as breast cancer and nine other types of cancer. The company is currently conducting a pharmacoeconomic study as a basis for future discussions with health insurance companies. After obtaining the CE mark, the company plans to launch the Giasay® test on the Austrian and German market and expand sales through a network of well-known laboratories.

Their innovative method shows increased accuracy compared to procedures currently available in Europe. Glycanostics works with international partners and has the support of experienced professionals from the world of science and business. The company's potential for business success is confirmed by the high scalability of the product and the global commercial potential.

Why invest in Glycanostics?

To view this section, please register.

Team

To view this section, please register.

Product and technology

To view this section, please register.

Market and competition

To view this section, please register.

Business model and customers

To view this section, please register.

Risks

To view this section, please register.

The investment opportunity is available on the Crowdberry platform one year after the launch of the investment campaign itself. The campaign is therefore scheduled to close from a regulatory perspective by 9 February 2025 at the latest.

€5,000,000
Target amount
€4,576
Min. investment
35 - 70% p.a.
Required return
€1,407,483
Interest
€1,793,544
Confirmed
262
Investors

You need to register to invest

Already registered? Log in

Documents





1
Registration
Sign up to access public investment documents as well as events
2
Indication of interest
Non-binding, to access investment documentation
3
Investment confirmation
Confirm the amount of your investment, upload the documents and fill out your data
4
Preparation and signing of contracts
We prepare the contracts and send them to you by email for signing.
5
You become an investor
Transfer the money and become investor in the company